Relmada Therapeutics (RLMD) Tops Q4 EPS by 3c
Tweet
Share
E-mail
Get Alerts RLMD Hot Sheet
Join SI Premium – FREE
Relmada Therapeutics (NASDAQ: RLMD) reported Q4 EPS of ($1.80), $0.03 better than the analyst estimate of ($1.83).
For earnings history and earnings-related data on Relmada Therapeutics (RLMD) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Tesla to launch Cybercab in Austin this month - report
- Haemonetics signs non-exclusive supply deal with CSL Plasma
- Baidu (BIDU) Misses Q2 EPS by 262c, misses on revenue
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
